Silo Pharma, Inc. · NASDAQ:SILO
Silo Pharma — Investor Presentation (March 2025)
18 slides from Silo Pharma's investor presentation, March 2025
Slide 1: Novel Therapeutics for Unmet Medical Needs
NOVEL THERAPEUTICS FOR UNMET MEDICAL NEEDS Investor Presentation March 2025
Slide 2: Forward-Looking Statements
Nasdaq: SILO FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”,
Slide 3: Unmet Medical Needs
Nasdaq: SILO Novel Therapeutics for Post-traumatic stress disorder (PTSD) UNMET MEDICAL NEEDS Stress-induced psychiatric disorders Fibromyalgia and chronic pain disorders We are a developmental stage Central nervous system (CNS) diseases biopharmaceutical company developing novel therapeutics Our fo
Slide 4: Multiple Levers for Value Creation
Multiple Levers for VALUE CREATION Nasdaq: SILO • Clear timeline to first-in-human clinical trials for lead asset SPC-15 pending FDA guidance on pre-IND. • Exclusive global licenses granted by Columbia University for two portfolio assets. • Streamlined 505(b)(2) regulatory pathway for drug approval
Slide 5: Under-Addressed Medical Needs
Under-Addressed MEDICAL NEEDS Nasdaq: SILO Mental Health Neurology Chronic Pain SPC-15 | Intranasal PTSD treatment SPC-14 | Alzheimer’s Disease SP-26 | Non-opioid pain solution • Selective intranasal drug • Potential to improve and restore • Ketamine-based therapeutic compound (non-psychedelic) cogn
Slide 6: Silo Pharma's Drug Pipeline
Nasdaq: SILO Silo Pharma’s DRUG PIPELINE Our current assets have shown promise in a range of diseases and conditions including PTSD, chronic pain, Alzheimer’s Disease, and multiple sclerosis. 6
Slide 7: SPC-15: Prophylactic Treatment for PTSD
SPC-15: Nasdaq: SILO PROPHYLACTIC TREATMENT FOR PTSD Blood Brain Barrier Drug: INTRODUCTION • Novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment Stage: Lorem ipsum dolor sit amet, consectetur adipiscing elit, • Pre-IND submitted sed do eiusmod tempor incididunt for fir
Slide 8: SP-26: Ketamine Implant for Fibromyalgia
SP-26: Nasdaq: SILO KETAMINE IMPLANT FOR FIBROMYALGIA Drug: • Subcutaneous time-released ketamine-based injectable dissolvable implant Stage: • Preclinical research Unmet need: • Only FDA-approved drugs for fibromyalgia are 2 antidepressants and 1 anti-seizure medicine1 • Chronic pain treatment mark
Slide 9: Neurology Programs
Nasdaq: SILO NEUROLOGY PROGRAMS SPC-14:ALZHEIMER’S DISEASE SPU-16:MULTIPLE SCLEROSIS Drug: Drug: • Novel drug targeting two receptor molecules • Central nervous system homing peptide Stage: Stage: • Preclinical research • Preclinical research Unmet need: Unmet need: • Treatment market projected grow
Slide 10: Pipeline
Nasdaq: SILO PIPELINE Drug and Optimization/ Indication Preclinical Phase I Phase II Phase III Launch Catalysts Category Proof of Concept Stress-Induced SPC-15 IND expected Affective Mental Health in 2025 Disorders JANUARY FEBRUARY MARCH APRIL SP-26 Data in 45-60 Fibromyalgia Lorem ipsum dolor sit a
Slide 11: Creating Value
Nasdaq: SILO Creating VALUE Our strategic business platform supports our ongoing development of novel drugs with the potential to transform patient care. 11
Slide 12: FDA's 505(b)(2) Abbreviated Regulatory Pathway
FDA’s 505(b)(2) Nasdaq: SILO ABBREVIATED REGULATORY PATHWAY Silo Pharma intends to utilize the FDA’s streamlined 505(b)(2) pathway for its top two priority drug candidates, SPC-15 and SP-26. Section 505(b)(2) of the Federal Food, Drug, and Cosmetics Act (FDCA) • Streamlined pathway to New Drug Appli
Slide 13: Management and Key Personnel
MANAGEMENT Nasdaq: SILO Eric Weisblum CEO ◉ 20+ years investing, building and managing businesses ◉ Prior president of Sableridge Capital ◉ Former board member of Aikido Pharma, a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics Daniel Ryweck CFO ◉ Certified Pu
Slide 14: Scientific Advisory
Nasdaq: SILO SCIENTIFIC ADVISORY Charles B. Nemeroff M.D., Ph.D. ◉ Chair, Department of Psychiatry and Behavioral In addition to our work with world- Sciences, Dell Medical School, University of renowned educational institutions, Texas at Austin; director, Institute for Early Life we engaged a scien
Slide 15: Board of Directors
BOARD OF DIRECTORS Nasdaq: SILO Eric Weisblum CEO Wayne Linsley Director ◉ 20+ years investing, building and managing ◉ 40 years in business management businesses ◉ Wide and varied skillset including sales and sales ◉ Prior president of Sableridge Capital management, finance (public and private ◉ Fo
Slide 16: Key Collaborations and Intellectual Property
Key Collaborations and Nasdaq: SILO INTELLECTUAL PROPERTY Exclusive collaborations with prominent medical research partners CRO & Manufacturing provide valuable IP, assets, and time-to-market advantages. Partners include… Columbia University • Exclusive worldwide rights to develop, manufacture, and
Slide 17: Creating Value
Creating VALUE Nasdaq: SILO SPC-15 SP-26 502(b)(2) Exclusivity Pathway to Non-opioid Streamlined pathway Strong asset first-in-human pain relief to FDA approval protection trials Market Size Partners Credentials Capital Large CNS Prominent Broad life sciences Sufficient markets collaborations expert
Slide 18: Thank you.
Nasdaq: SILO Thank you. Silo Pharma, Inc. | 677 N. Washington Blvd., Sarasota, FL 34236 Investor Relations Contact: 800-705-0120 | investors@silopharma.com 18